Shares of Cesca Therapeutics Inc. (KOOL) were transacted with a volume of 35893 shares in last trading period as compared to its average volume of 342K shares over last three months period. The stock price scored -3.03% and valued at $0.3.
Cesca Therapeutics Inc. a USA based Company, belongs to Healthcare sector and Medical Appliances & Equipment industry. Shares of the company returned -5.94% during the last five trading days and it returned 15.15% in past 30 trading days. It changed -21.37% over recent three months. The stock has changed -89.87% in one year period and YTD Performance clocked at 12.78%.
ThermoGenesis Corp, a private corporation owned by Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, today announced the construction and qualification of a new Class 100,000, GMP compliant assembly facility to manufacture all X-Series cell processing disposables.
Haihong Zhu, President of ThermoGenesis, stated, “Now that we have completed the transfer of assembly of both our cell processing disposables and automated Control Module and Docking Station devices from third-party vendors to our in-house facility in Rancho Cordova, we have better control over our supply chain and are able to provide even higher quality products and improved customer service. Equally important, ThermoGenesis is now better equipped to scale its manufacturing rate to keep pace with the rising demand for the X-Series ‘closed system’ automated cell processing products.” These products include:
• The X-LAB® System, for harvesting purified mononuclear cells from blood or bone marrow
• The X-WASH® System, for washing contaminants from cell suspensions
• The PXP® System, for “Point of Care” harvesting of purified mononuclear cells and platelets from blood or bone marrow
The price moved ahead 6.12% from the mean of 20 days, -0.67% from 50 and separated -44.58% from 200 days average price. Its price volatility for a month is at 11.96% and for a week, volatility remained at 7.85%. It beta stands at 0.65. Company’s price to sales ratio for last 12 months was 0.68 while its price to book ratio for the most recent quarter was 0.43. Its Market Cap valued at $6.7M.